VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens' Prediction.

ABSTRACT: Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes. Previous studies demonstrated that only a limited subset of mutations generates neoantigens in microsatellite stable tumors. We developed a method, called VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection), to prioritize mutated peptides with high potential to be neoantigens. Our method assigns to each mutation a weighted score that combines the mutation allelic frequency, the abundance of the transcript coding for the mutation, and the likelihood to bind the patient's class-I major histocompatibility complex alleles. By ranking mutated peptides encoded by mutations detected in nine cancer patients, VENUS was able to select in the top 60 rank

SUBMITTER: Leoni G 

PROVIDER: S-EPMC8402534 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature